Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

NETWORK 10 OTHER 4 NIH 4 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 9 Gynecologic 3 Gastrointestinal 3 Other solid neoplasm 2 Head & Neck 1 Genitourinary 1 CNS 1 Breast 1

Conditions

Interventions

Temozolomide 123 Radiotherapy 47 Bevacizumab 46 Lomustine 25 Radiation 20 Nivolumab 17 Irinotecan 16 Carboplatin 16 Cyclophosphamide 14 Granulocyte-Macrophage Colony-Stimulating Factor 13 pembrolizumab 11 dabrafenib 10 Trastuzumab 10 Surgical Procedures, Operative 10 Capecitabine 10 paclitaxel-Angiopep-2 conjugate 8 TIC10 compound 8 Paclitaxel 8 Gemcitabine 8 Carmustine 8 trametinib 7 Topotecan 7 IL13-PE38 7 Everolimus 7 Drug Therapy 7 Aminolevulinic Acid 7 AZD 6244 7 3-Iodobenzylguanidine 7 fludarabine 6 enzastaurin 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Platinum × CNS × Clear all

NCT07138001 2025-08-22

Phase 2 Clinical Trial of KH617

Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Phase 2 Not yet recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡